Data / Form D filings / Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc.: Form D filings
Reunion Neuroscience, Inc., a pharmaceuticals company in Morristown, NJ, filed 4 Form D notices with the SEC between 2024 and 2025. The latest, on September 9, 2025, reports $119.9 million sold of a $119.9 million offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1 HIGH STREET COURT, Morristown, NJ, 07960
- Phone
- (888) 880-7386
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2023
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2007993
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2025 | Amendment | $119,850,000 | $119,850,000 | 9 | Jan 12, 2024 | sec.gov | |
| May 5, 2025 | Amendment | $89,850,000 | $68,880,305 | $20,969,695 | 9 | Jan 12, 2024 | sec.gov |
| May 6, 2024 | Amendment | $89,850,000 | $33,668,182 | $56,181,818 | 9 | Jan 12, 2024 | sec.gov |
| Jan 25, 2024 | New notice | $66,850,000 | $16,850,000 | $50,000,000 | 6 | Jan 12, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Gregory Mayes | Executive Officer, Director | |
| Michael Ehlers | Director | |
| Ansbert Gadicke | Director | |
| Natalie Sacks | Director | |
| Ellen Lubman | Director | |
| Mark Pollack | Executive Officer | |
| Alon Lazarus | Director | |
| Nathan Bryson | Executive Officer | |
| Mark Theeuwes | Executive Officer | |
| Edward Smith | Executive Officer |
Other pharmaceuticals companies in New Jersey that filed recently
- Grace Therapeutics, Inc. $10 million · Aug 11, 2026
Every Form D from the week of Sep 8, 2025 · All recent filings in New Jersey · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Reunion Neuroscience, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.